All articles tagged with #prescription drugs
CVS Health’s CEO David Joyner says private employers aren’t ready to broadly cover GLP-1 weight-loss drugs like Ozempic because of high costs and uncertain long-term savings; prices need to come down and there must be clear evidence they reduce overall health care costs before broader coverage resumes, even as Medicare moves to cover GLP-1s.
A Yale secret-shopping study in which a Yale medical student posed as a 237-pound patient found that most online GLP-1 weight-loss drug vendors provide lax clinical oversight; only 13 of 49 sites required video consultations, with many relying on unverified online questionnaires, raising patient-safety concerns amid the GLP-1 drug boom.
Colorado has FDA approval to import 20 prescription drugs from Canada, including Ozempic and Eliquis, in a bid to lower costs—potentially 20–70% cheaper per drug and about $46 million in savings over three years—though availability will depend on Canada’s supply and manufacturers’ participation; safety and supply-chain concerns persist, and Florida is the only other state with a similar approval.
Eli Lilly’s experimental GLP-1 drug retatrutide produced an average 28% weight loss in obese patients, a striking boost over existing GLP-1 therapies, but doctors warn that greater potency can bring new safety risks; the company expects to file for FDA approval by 2026.
The Washington Post reports that some people with anorexia, bulimia, or binge eating disorder are using GLP-1 weight-loss medications, prompting alarm from doctors about safety and the need for careful monitoring of vulnerable patients, as anecdotal stories highlight the risk and complexity of treating eating disorders with these drugs.
The FDA granted expanded access to Revolution Medicines’ pancreatic cancer drug daraxonrasib, allowing more patients to use the treatment while it remains under regulatory review. In trials the drug showed promise, including doubling survival time in some studies, raising hopes that approval could come later in the year.
TrumpRx.gov, launched to curb prescription costs, has offered discounts on only 54 drugs—many with cheaper generics or other savings options—and remains far from an insurance-friendly tool, with limited awareness; experts say its real impact hinges on scale, broader drug coverage, price transparency, and potential congressional action to codify MFN-style deals into law.
The Trump administration unveiled TrumpRx, a White House-backed website intended to help patients buy prescription drugs directly at discounted rates, as part of a push to address rising healthcare and living costs.
President Trump is rolling out TrumpRx.gov, a government site intended to help Americans buy discounted prescription medicines as part of his broader bid to extract price concessions from drugmakers; experts say the plan could offer some savings but is unlikely to dramatically lower costs or reshape the pharmaceutical market.
President Trump released a health-care framework called the Great Health Care Plan that would lower prescription drug prices, shift ACA subsidies toward Health Savings Accounts, and require price transparency from insurers, hospitals, and physicians. The proposal also seeks congressional passage of a most-favored-nation drug pricing policy and funding for ACA cost-sharing reductions to reduce premiums, though some elements are likely to draw GOP pushback on Capitol Hill.
President Trump unveils The Great Healthcare Plan, promising to lower costs by slashing prescription prices, reducing insurance premiums by redirecting subsidies to individuals, expanding funding for cost-sharing reductions, and enforcing price transparency from insurers and providers, including publishing prices and denial rates to empower consumers.
A new Medicare claims analysis found that about 25% of people with dementia are prescribed risky, brain-altering medications such as antidepressants and antipsychotics, despite longstanding clinical guidelines cautioning against this practice.
In 2026, Medicare beneficiaries will face increased premiums and deductibles, higher out-of-pocket costs for prescription drugs, and new negotiated rates on 10 common medications, making it crucial to review plans and budget accordingly for retirement healthcare expenses.
The article discusses how U.S. seniors increasingly rely on cheaper Canadian and international pharmacies for prescription medications, but recent trade policies, tariffs, and shipment restrictions are making access more difficult and expensive, raising concerns about affordability and safety.
Amazon is introducing vending machines at One Medical clinics in Los Angeles to allow patients to quickly pick up common prescriptions like antibiotics and blood pressure medication, aiming to improve access and reduce delays in medication collection. These kiosks will not dispense controlled substances and will be available at more locations in the future, with added options for phone and video consultations with pharmacists.